At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
Upadacitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating Upadacitinib and Placebo for Hidradenitis Suppurativa (HS). Completed, enrolled 68 participants across 26 sites in 4 countries.
Detailed Summary
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions. This study will evaluate how well upadacitinib compared to placebo (no medicine) works to treat hidradenitis suppurativa in adult participants with moderate to severe disease. The study will assess change in disease signs and symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa (HS)
CountriesCanada, Japan, Puerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionApr 2021
Study CompletionJan 2022
TodayJul 2026
First PostedJun 12, 2020
Enrollment StartJul 14, 2020
Primary CompletionApr 22, 2021
Study CompletionJan 25, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.1 years ago
Interventions
Upadacitinibdrug
Tablet; Oral
Placebodrug
Tablet; Oral